Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges - PubMed (original) (raw)

Review

Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges

Jean-François Dufour et al. Gut. 2020 Oct.

Abstract

Non-alcoholic steatohepatitis (NASH) is becoming a leading cause of cirrhosis with the burden of NASH-related complications projected to increase massively over the coming years. Several molecules with different mechanisms of action are currently in development to treat NASH, although reported efficacy to date has been limited. Given the complexity of the pathophysiology of NASH, it will take the engagement of several targets and pathways to improve the results of pharmacological intervention, which provides a rationale for combination therapies in the treatment of NASH. As the field is moving towards combination therapy, this article reviews the rationale for such combination therapies to treat NASH based on the current therapeutic landscape as well as the advantages and limitations of this approach.

Keywords: hepatobiliary disease; liver; nonalcoholic steatohepatitis.

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

PubMed Disclaimer

Conflict of interest statement

Competing interests: CC received consultant fees from NovoNordisk, AstraZeneca, Gilead. J-FD Advisory committees: Bayer, BMS, Falk, Genfit, Genkyotex, Gilead Science, HepaRegenix, Intercept, Eli Lilly, Merck, Novartis; Speaking and teaching: Bayer, BristolMyers Squibb, Intercept, Genfit, Gilead Science, Novartis. RL serves as a consultant or advisory board member for Arrowhead Pharmaceuticals, AstraZeneca, Bird Rock Bio, Boehringer Ingelheim, Bristol-Myer Squibb, Celgene, Cirius, CohBar, Conatus, Eli Lilly, Galmed, Gemphire, Gilead, Glympse bio, GNI, GRI Bio, Intercept, Ionis, Janssen, Merck, Metacrine, NGM Biopharmaceuticals, Novartis, Novo Nordisk, Pfizer, Prometheus, Sanofi, Siemens, and Viking Therapeutics. In addition, his institution has received grant support from Allergan, Boehringer-Ingelheim, Bristol-Myers Squibb, Cirius, Eli Lilly and Company, Galectin Therapeutics, Galmed Pharmaceuticals, GE, Genfit, Gilead, Intercept, Grail, Janssen, Madrigal Pharmaceuticals, Merck, NGM Biopharmaceuticals, NuSirt, Pfizer, pH Pharma, Prometheus, and Siemens. He is also cofounder of Liponexus.

Figures

Figure 1

Figure 1

(A) Percentage of patients with resolution of non-alcoholic steatohepatitis (NASH) defined as ballooning 0 and inflammation 0–1, without worsening fibrosis in placebo and intervention arms of randomised clinical trials showing an effect. (B) Percentage of patients with more than one-stage improvement in fibrosis without worsening of NASH in placebo and intervention arms of randomised clinical trials showing an effect. The references are provided in the text, the data for the obeticholic acid phase 3 are based on study by Sanyal et al.

Figure 2

Figure 2

Rationale for combination therapy to treat non-alcoholic steatohepatitis (NASH). Drugs with different mechanisms of action targeting hepatic steatosis, inflammation and fibrosis could be combined. Ideally, such combinations should be safe and have positive effects beyond the liver such as weight loss, cardiovascular protection, insulin sensitisation and lipid reduction.

References

    1. Younossi ZM, Ratziu V, Loomba R, et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 2019;394:2184–96. 10.1016/S0140-6736(19)33041-7 - DOI - PubMed
    1. Sanyal AJ, Ratziu V, Loomba R, et al. Obeticholic acid treatment in patients with non alcoholic steatohepatitis: a secondary analysis of the regenerate study across fibrosis stages. Hepatology 2019:23A.
    1. Tropifexor SA. A highly potent FXR agonist, produces robust and dose-dependent reductions in hepatic fat and serum alanine aminotransferase in patients with fibrotic NASH after 12 weeks of therapy: FLIGH-FXR part C interim results. Hepatology 2019;70.
    1. Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 2015;385:956–65. 10.1016/S0140-6736(14)61933-4 - DOI - PMC - PubMed
    1. Traussnigg S, Schattenberg JM, Demir M, et al. Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial. Lancet Gastroenterol Hepatol 2019;4:781–93. 10.1016/S2468-1253(19)30184-0 - DOI - PubMed

Publication types

MeSH terms

Grants and funding

LinkOut - more resources